# Neumous

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neumous

- Industry: Medical Devices & Equipment
- Headquarters: Cheongju-si, South Korea
- Website: www.neumous.com/
- Total disclosed funding: $7M
- Latest round: Series A (Jul 15, 2025)
- Investors on record: 5

## About

Based in South Korea, Neumous Inc. operates as a pioneering company developing therapeutic ultrasound medical devices, focusing on innovative, non-invasive methods for treating brain diseases.Neumous Inc. specializes in creating advanced therapeutic ultrasound solutions aimed at facilitating drug delivery across the blood-brain barrier. Founded in 2022 and headquartered in Cheongju-si, South Korea, the company raised KRW 9.6 billion in Series A funding on July 15, 2025, from investors including AJU IB Investment, STIC Ventures, SL Investment, and IBK Venture Investment, with returning partner FuturePlay. The company has completed one funding deal to date, and its founder has a background in launching innovative medical technology firms.Neumous is at the forefront of developing innovative therapeutic ultrasound medical devices, primarily focused on non-invasive solutions for opening the blood-brain barrier (BBB). Their core offering utilizes focused ultrasound technology to precisely target specific brain regions, allowing for the direct delivery of therapeutic agents intended to treat a variety of brain diseases, including brain tumors and Alzheimer's disease. This approach eliminates the need for traditional surgical interventions, providing significant advancements in personalized treatment. The company’s devices, officially released in January 2024 and December 2024, aim to serve healthcare providers, pharmaceutical companies, and research institutions across global markets, including North America, Europe, and Asia. By offering real-time monitoring capabilities, Neumous ensures that treatments can be tailored to individual patient needs, thereby maximizing therapeutic efficacy.Neumous generates revenue through strategic partnerships with pharmaceutical companies and healthcare institutions that utilize its ultrasound-BBB opening technology in clinical settings. The revenue model is based on B2B transactions, where healthcare providers and research entities purchase their ultrasound devices or the associated therapeutic services. The company’s flagship product, which enables BBB opening for drug delivery, is expected to be priced to reflect its innovative capabilities and clinical value. Partnerships may also involve collaborative research projects funded by governmental grants, enhancing the financial support for the development and deployment of their technologies. The specific transaction structures and pricing plans are designed to accommodate the unique needs of clients in the medical field, ensuring broad accessibility to their advanced therapeutic solutions.In July 2025, Neumous Inc. raised KRW 9.6 billion in Series A funding to enhance its operational capacity. The company plans to utilize this funding to hire additional research employees and accelerate its clinical trials. Future product launches are anticipated, particularly in expanding the application of their ultrasound technology in new therapeutic areas. Neumous is targeting expansion into markets across North America and Europe by 2026, aiming to solidify its presence in these regions with innovative medical solutions.

## Funding rounds

- Series A, Jul 15, 2025, $7M — AJU IB Investment, SL Investment, FuturePlay, STIC Ventures, IBK Venture Investment

## Investors

- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series A
- SL Investment (https://capitalatlas.ai/funds/sl-investment) — Series A
- FuturePlay (https://capitalatlas.ai/funds/futureplay) — Series A
- STIC Ventures (https://capitalatlas.ai/funds/stic-ventures) — Series A
- IBK Venture Investment (https://capitalatlas.ai/funds/ibk-venture-investment) — Series A